SYRE

Spyre Therapeutics (formerly Aeglea BioTherapeutics) is a clinical-stage biotech reshaped around a portfolio of next-generation monoclonal antibodies for inflammatory bowel disease (ulcerative colitis, Crohn's) and other immune-mediated diseases — the SPY001 (alpha-4-beta-7 integrin), SPY002 (TL1A) and SPY003 (IL-23) programs licensed from Paragon. It has no commercial product and generated zero product revenue in FY2025; the only revenue history is a small legacy gain tied to the pegzilarginase sale to Immedica, the proceeds of which largely flow to CVR holders. This is a pipeline story whose value is entirely contingent on clinical and regulatory success.

The financials confirm the pre-commercial profile: a $155M net loss (an improvement of 25.4% but still a deep loss), a -$210M operating loss, and -$169M of operating cash burn, against a -21.7% return on equity. The redeeming feature is the balance sheet — total assets of $778M (+27.8%, essentially all current), equity of $715M (+38.1%), and minimal liabilities ($62.5M, 0.09x leverage) — though reported cash and equivalents of $85.7M is only part of the liquid asset base, and shares outstanding grew 30.3% as the company raised capital. The funding cushion meaningfully de-risks the near-term runway relative to its burn.